Home | Business News | Browse by Publication | P | PR Newswire

Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting.

Article Excerpt
WAYNE, N.J. and EMERYVILLE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced that more than 25 studies evaluating the use of NexavarA' (sorafenib) tablets in liver cancer will be presented at The Liver MeetingA', the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Nexavar is the only systemic treatment to demonstrate prolonged survival in patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, and is currently approved in more than 80 countries for the treatment of the disease.

"Bayer and Onyx are committed to further evaluating Nexavar in patients with HCC to find the safest and most effective treatment regimens to help liver cancer patients better manage their disease," said Mark Gelder, vice president, Bayer Global Medical Affairs, Oncology. "While we are encouraged by the role Nexavar has played in treating these patients, we continue to evaluate Nexavar in a variety of treatment settings, including in combination with TACE and other systemic therapies, and as a monotherapy in the adjuvant setting."

Nexavar data highlights include:

Phase II Trial of Sorafenib...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!